GIELDA PAPIERÓW WARTOSCIOWYCH W WARSZAWIE S.A. 10
The company GENOMTEC S.A. was newly listed on the GPW Main Market on 16 February 2023.
GENOMTEC S.A. is the 418th company listed on the Main Market and the fourth new listing on the Main Market in 2023.
company name | GENOMTEC S.A. |
companies listed on the market | 418 |
new listings in 2023 | 4 (transfer from NewConnect) |
market (main/parallel) | parallel |
business sector | New Technology |
companies in the sector | 7 |
seat | Wrocław |
Polish/foreign | Polish company |
core business | Genomtec S.A. conducts research and development work in the area of application of isothermal methods in molecular diagnostics. |
IPO/public sale (Y/N) | In connection with the admission of the shares to trading on the regulated market, the Company did not conduct an offering of "new" shares |
issue/selling price | in the absence of a public offering, no issue/selling price was determined |
public offering value | not applicable |
reference price | equal to the closing price on the last day of trading on NewConnect |
company valuation* | PLN 87,058,687.8 |
% free float | 68.72% |
free float value* | PLN 55,147,324.39 |
% free float in all shares | 71.16% |
free float value* | PLN 61,954,998.16 |
Investment Firm | Dom Maklerski INC SA |
Legal Advisor | Wardyński i Wspólnicy sp.k. |
Auditor | Firma audytorska 4AUDYT sp. z o.o. |
*based on the average price of the Company's shares in the NC ATS for the last 3 months preceding the date of filing the application for admission, equal to PLN 8.57.
ISSUER'S HISTORY AND BUSINESS
The Company's shares were listed in the NewConnect Alternative Trading System from 17 March 2021.
Genomtec S.A. was founded in 2016 by a group of scientists and engineers with experience and competence in molecular biology, microsystems and photonics.
The company (its offices and laboratories) is located at the Łukasiewicz Research Network, Polish Technology Development Centre (PORT) in Wrocław, 147 Stabłowicka Street.
Genomtec S.A. conducts research and development work in the area of application of isothermal methods in molecular diagnostics.
The company's flagship project is the Genomtec ID, a diagnostic system with the potential to become a new standard in diagnostics thanks to the mobility, speed and efficiency of the device, which makes it possible to detect pathogens such as viruses, bacteria, fungi, as well as genetic mutations by analysing biological material: swabs, urine, saliva.
The Genomtec ID is a handy cube-shaped diagnostic system measuring approximately 10cm x 10cm x 15cm, which offers mobility and speed of testing while maintaining the highest standards of sensitivity and specificity. The Genomtec ID will be able to test up to five pathogens simultaneously on a single reaction card, which in the Management Board's opinion represents optimum information value for the test analyser.
Another area of the Company's business is the development and commercialisation of genetic tests with applications including the detection of viral infectious diseases, such as COVID-19 caused by the SARS-CoV-2 virus. However, the Management Board considers the testing business as a side activity as the Genomtec ID is the Company's most important project.
The share capital of the Company amounts to PLN 1,015,854.00 and is divided into 10,158,540 shares with a nominal value of PLN 0.10 each, including:
- 1,000,000 series A ordinary bearer shares,
- 142,860 series B ordinary bearer shares,
- 4,000,000 series C ordinary bearer shares,
- 583,670 series D ordinary bearer shares,
- 85,900 series E ordinary bearer shares,
- 76,000 series F ordinary bearer shares,
- 710,110 series G ordinary bearer shares,
- 830,000 series H ordinary bearer shares,
- 730,000 series J ordinary bearer shares,
- 1,205,639 series K ordinary bearer shares,
- 794,361 series L ordinary bearer shares.
Issuer's selected financials (PLN):
Q1-3 2022 |
2021 (PLN) |
2020 (PLN) |
2019 (PLN) | |
Sales revenue | 22,000.00 | 219,000.00 | 20,000.00 | 153,000.00 |
Grants received | 518,000.00 | 3,185,000.00 | 3,627,000.00 | 1,365,000.00 |
Net loss | (5,343,000.00) | (7,115,000.00) | (10,939,000.00) | (1,462,000.00) |
Equity | 2,555,000.00 | 723,000.00 | 7,572,000.00 | 1,090,000.00 |
Non-current liabilities | 3,532,000.00 | 926,000.00 | 689,000.00 | 598,000.00 |
Current liabilities | 2,335,000.00 | 2,567,000.00 | 1,110,000.00 | 1,194,000.00 |
Total assets | 8,423,000.00 | 4,216,000.00 | 9,371,000.00 | 2,882,000.00 |
Net cash flows | 593,000.00 | (5,937,000.00) | 5,875,000.00 | 1,082,000.00 |
Cash and cash equivalents at the end of the period | 1,954,000.00 | 1,361,000.00 | 7,298,000.00 | 1,423,000.00 |
Securities admitted to trading on the regulated (parallel) market
- 1,000,000 series A ordinary bearer shares,
- 142,860 series B ordinary bearer shares,
- 4,000,000 series C ordinary bearer shares,
- 583,670 series D ordinary bearer shares,
- 85,900 series E ordinary bearer shares,
- 76,000 series F ordinary bearer shares,
- 710,110 series G ordinary bearer shares,
- 830,000 series H ordinary bearer shares,
- 730,000 series J ordinary bearer shares,
- 1,205,639 series K ordinary bearer shares,
- 794,361 series L ordinary bearer shares.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
WSE - Warsaw Stock Exchange SA published this content on 16 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 February 2023 18:16:24 UTC.
